Merck’s fourth-quarter results top estimates, fueled by key cancer ...
WEBFeb 1, 2024 · Merck & Co. Inc. on Thursday reported fourth-quarter earnings and sales that beat analysts’ expectations, powered by strong growth in cancer and vaccine products.
Merck's Q2 Earnings: Revenue And EPS Beat Helped By Strong …
WEBJul 30, 2024 · MRK. Merck's Q2 Earnings: Revenue And EPS Beat Helped By Strong Keytruda Sales, But Acquisition Costs Bites Into Annual Profit Forecast. On Tuesday, Merck & Co Inc (NYSE: MRK) reported...
Merck: KEYTRUDA Plus Chemotherapy Gets FDA Approval For …
WEB2 days ago · (RTTNews) - Drug major Merck & Co., Inc. (MRK) announced Wednesday that the U.S. Food and Drug Administration has approved its anti-PD-1 therapy KEYTRUDA (pembrolizumab), in combination with ...
Merck's wins FDA approval for Keytruda in combination
WEB2 days ago · Merck & Co. Inc. (MRK) said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda in combination with pemetrexed and platinum chemotherapy as a first ...
Merck wins first FDA approval for Keytruda as a treatment for ...
WEB2 days ago · Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated ...
Merck Launches First Ever AI Solution to Integrate Drug Discovery …
WEBDec 5, 2023 · Merck, a leading science and technology company, today launched its AIDDISON™ drug discovery software, the first software-as-a-service platform that bridges the gap between virtual molecule ...
News releases - Merck.com
WEB6 days ago · September 11, 2024. Merck Announces Positive Top-line Results from Phase 3 Trial Evaluating Efficacy and Safety of GARDASIL®9 in Japanese Males. September 07, 2024. Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in …
Merck's Keytruda Obtains its First FDA Approval for Mesothelioma
WEB1 day ago · September 19, 2024 — 10:21 am EDT. Merck & Co., Inc. MRK announced that the FDA had approved its blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), for a new indication. The regulatory ...
Merck Keytruda approved by FDA for mesothelioma (NYSE:MRK)
WEB2 days ago · Merck & Co., Inc. (MRK) CEO Rob Davis presents at Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript) Updating Walmart, Merck And Nike Post-Earnings Merck, Daiichi post late-stage ...
Merck Announces Fourth-Quarter and Full-Year 2023 Financial …
WEBFeb 1, 2024 · Initiated More Than 20 Phase 3 Study Starts, Including the Progression of Eight Novel Assets Into Phase 3 in 2023. Augmented Pipeline Through Acquisitions of Prometheus and Imago, and Collaboration Agreements With Daiichi Sankyo and Kelun-Biotech in 2023. Full-Year 2024 Financial Outlook.